Back to top
more

Terumo (TRUMY)

(Delayed Data from OTC)

$19.59 USD

19.59
138,006

+0.45 (2.35%)

Updated Nov 5, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Recent Price Trend in Terumo (TRUMY) is Your Friend, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Terumo (TRUMY) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Terumo (TRUMY) Should Keep going

by Zacks Equity Research

Terumo (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Are You Looking for a Top Momentum Pick? Why Terumo Corp. (TRUMY) is a Great Choice

by Zacks Equity Research

Does Terumo Corp. (TRUMY) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Terumo (TRUMY) a New Buy Stock

by Zacks Equity Research

Terumo (TRUMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

by Zacks Equity Research

Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.

Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results

by Zacks Equity Research

Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.

Terumo (TRUMY) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Terumo (TRUMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stocks to Buy for March 28th

by Zacks Equity Research

TRUMY, CIFR and STR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 28, 2023.

New Strong Buy Stocks for March 28th

by Zacks Equity Research

XRX, REYN, TRUMY, DQ and STR have been added to the Zacks Rank #1 (Strong Buy) List on March 28, 2023.

Here's What Could Help Terumo Corp. (TRUMY) Maintain Its Recent Price Strength

by Zacks Equity Research

Terumo Corp. (TRUMY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes Terumo Corp. (TRUMY) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Terumo Corp. (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Terumo Corp. (TRUMY) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Terumo Corp. (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Terumo Corp. (TRUMY) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Terumo Corp. (TRUMY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in Terumo Corp. (TRUMY) is Your Friend, Here's Why

by Zacks Equity Research

Terumo Corp. (TRUMY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space

by Zacks Equity Research

Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.

Terumo's (TRUMY) MicroVention Enters Transradial Access Space

by Zacks Equity Research

The SOFIA EX 5F Catheter by Terumo's (TRUMY) MicroVention boasts a new design to enhance trackability.

Boston Scientific (BSX) Looks Good: Stock Adds 7.4% in Session

by Zacks Equity Research

Boston Scientific (BSX) shares rose more than 7% in the last trading session, amid huge volumes.

    ICU Medical (ICUI) in Focus: Stock Moves 10.2% Higher

    by Zacks Equity Research

    ICU Medical (ICUI) saw its shares rise over 10% on the day.

      Haemonetics (HAE) in Focus: Stock Moves 10% Higher

      by Zacks Equity Research

      Haemonetics (HAE) saw its shares rise nearly 10% on the day after the company reported better-than-expected second quarter and first Half Fiscal 2018 results.

        Stryker (SYK) Catches Eye: Stock Jumps 7.3%

        by Zacks Equity Research

        Stryker Corporation (SYK) saw its shares rise over 7% on the day after the company reported better-than-expected third-quarter results.

          NuVasive (NUVA) in Focus: Stock Moves 8.4% Higher

          by Zacks Equity Research

          NuVasive, Inc. (NUVA) saw its shares rise over 8% on the day after the company reported better-than-expected third-quarter results and announced a major stock repurchase program.

            MedTech Growing on Emerging Markets, M&A: Stocks to Buy

            by Zacks Equity Research

            Given the current lack of clarity, let???s concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation.